|
|
Vol. 11.12 – 31 March, 2022
|
|
|
|
|
|
|
|
Using a non-human primate model of lung injury with human organoids and tissue specimens, researchers showed that alveolar type-2 cells in regenerating lungs transiently acquired an alveolar type-0 state from which they could differentiate into either alveolar type-1 cells or respiratory bronchiole-secretory cells. [Nature]
|
|
|
|
|
|
PUBLICATIONSRanked by the impact factor of the journal
|
|
|
|
|
|
In human bronchial epithelial cells, phosphoinositide 3-kinase γ (PI3Kγ) mimetic peptide induced unexpected cyclic adenosine monophosphate and protein kinase A elevations restricted to the vicinity of the CF transmembrane conductance regulator (CFTR). [Science Translational Medicine]
|
|
|
|
|
|
The authors reported that vaccinia C7 was a crucial virulence factor that blocked activation of the transcription factor IRF3.
[Nature Communications]
|
|
|
|
|
|
Investigators examined human airway epithelium infected with three different isolates of SARS-CoV-2 including the B.1.1.7 variant by transmission electron microscopy and tomography.
[Nature Communications]
|
|
|
|
|
|
To investigate viral spread, primary human airway epithelial cell cultures were infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and host–virus interactions were examined via electron microscopy, immunohistochemistry, RNA in situ hybridization, and gene expression analyses. [Proceedings of the National Academy of Sciences of the United States of America]
|
|
|
|
|
|
|
|
Investigators found that tripartite motif (TRIM) 46 promoted lung adenocarcinoma cell proliferation and cisplatin resistance by enhancing glycolysis.
[Cell Death & Disease]
|
|
|
|
|
|
In an in vitro study using lung cancer cell lines and human monocyte-derived macrophages, the conditioned medium from cancer cells was found to up-regulate programmed cell death-1 ligand 1 expression on macrophages via STAT3 activation.
[Cancer Immunology Immunotherapy]
|
|
|
|
|
|
TRPV1 expression in tumor tissues, primary cells and cell lines of lung adenocarcinoma, as well as the mechanism mediating its hyperexpression were systematically studied.
[Cancer Gene Therapy]
|
|
|
|
|
|
The authors demonstrated that HORMAD1 promoted the proliferation, migration and invasion of lung cancer cells both in vitro and in vivo by inducing epithelial–mesenchymal transition. [Cell Death Discovery]
|
|
|
|
|
|
Inhibition of progression of lung cancer cells induced by heterogeneous nuclear ribonucleoprotein K-knockdown was dependent on activation of p53 by the p53/p21/cyclin D1 pathway.
[Thoracic Cancer]
|
|
|
|
|
|
Researchers explored the potential mechanism of exosome-derived miR-631 targeting and regulating E2F family of transcription factor 2 to repress the malignant behavior of NSCLC cells. [Bioengineered]
|
|
|
|
|
|
|
|
|
Scientists cover the airway surface preparation strategies reported in literature, the advantages and disadvantages of each method, as well as a discussion about applying this concept in the clinic. [Gene Therapy]
|
|
|
|
|
|
The authors review evidence of NOD-like receptor (NLR) P3 activation in IPF, of NLRP3 inhibition in different animal models of fibrosis, and highlight the recent advances in direct and indirect NLRP3 inhibitors. [American Journal of Pathology]
|
|
|
|
|
|
|
|
Prometheus Biosciences, Inc. announced it has enrolled its first patient in the ATHENA-SSc-ILD trial, a placebo-controlled and statistically powered Phase II study of PRA023 in SSc-ILD.
[Prometheus Biosciences, Inc.]
|
|
|
|
|
|
Ribon Therapeutics announced the first patient has been dosed in the Phase Ib/II study of RBN-2397 in combination with the anti-PD-1 checkpoint inhibitor therapy, pembrolizumab, in patients with squamous cell carcinoma of the lung. [Ribon Therapeutics]
|
|
|
|
|
|
|
|
May 4 – 7, 2022 San Francisco, California, United States
|
|
|
|
|
|
|
|
|
|
|
The Ohio State University – Columbus, Ohio, United States
|
|
|
|
|
|
|
University of Pittsburgh School of Medicine – Pittsburgh, Pennsylvania, United States
|
|
|
|
|
|
|
Genentech, Inc. – South San Francisco, California, United States
|
|
|
|
|
|
|
Gilead Sciences – Foster City, California, United States
|
|
|
|
|
|
|
Fred Hutchinson Cancer Research Center – Seattle, Washington, United States
|
|
|
|
|
|